WG
PTGX icon

Winton Group’s Protagonist Therapeutics PTGX Stock Holding History

Winton Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
12,673
+1,202
+10% +$106K 0.05% 432
2025
Q4 		$1M Sell
11,471
-7,090
-38% -$580K 0.03% 482
2025
Q3 		$1.23M Buy
18,561
+1,128
+6% +$64.1K 0.05% 381
2025
Q2 		$964K Sell
17,433
-3,362
-16% -$161K 0.05% 442
2025
Q1 		$1.01M Sell
20,795
-5,973
-22% -$250K 0.06% 417
2024
Q4 		$1.03M Buy
26,768
+785
+3% +$34.2K 0.07% 344
2024
Q3 		$1.17M Buy
+25,983
New +$1.05M 0.08% 210
2021
Q3 		– Sell
-5,431
Closed -$244K – 1456
2021
Q2 		$244K Buy
+5,431
New +$179K 0.01% 1279
2020
Q4 		– Sell
-32,854
Closed -$642K – 1477
2020
Q3 		$642K Sell
32,854
-5,757
-15% -$108K 0.02% 1006
2020
Q2 		$682K Buy
38,611
+828
+2% +$10.4K 0.02% 1112
2020
Q1 		$267K Sell
37,783
-52,073
-58% -$390K 0.01% 1193
2019
Q4 		$633K Buy
89,856
+52,732
+142% +$524K 0.01% 1180
2019
Q3 		$446K Buy
+37,124
New +$468K 0.01% 1127

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Winton Group's PTGX Position: Q1 2026 in Review

Winton Group increased its Protagonist Therapeutics (PTGX) stake by 10% in Q1 2026, buying an estimated $106K and bringing the position to 12,673 shares worth $1.34M. The position accounts for 0.05% of the portfolio, ranked #432.

Winton Group first reported a position in PTGX in Q3 2019 and has held it in 13 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Winton Group held 12,673 shares of Protagonist Therapeutics worth $1.34M as of Q1 2026.
  • Winton Group bought 1,202 Protagonist Therapeutics shares in Q1 2026, an estimated $106K.
  • Protagonist Therapeutics made up 0.05% of Winton Group's portfolio in Q1 2026, its #432 holding.
  • Winton Group first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.